signal-regulatory protein a-1

Protein kinase inhibitors 1 hydrochlorid (Protein kinase inhibitors 1 hydrochlorid (1365986-44-2(free base))) is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.

Protein kinase affinity probe 1 is used for the functional identification of protein kinases (PKs).

(Met(O2)35)-Amyloid β-Protein (1-42) is a peptide [1].

Human PTHrP-(1-34)NH2, also known as PTH-Related Protein (1-34) amide for human, mouse, and rat, is the N-terminal fragment of PTHrP. This peptide induces hypercalcemia and is utilized in the study of humoral hypercalcemia of malignancy [1].

'(Tyr36)-pTH-Related Protein (1-36) (human, mouse, rat), a peptide, functions as a ligand for parathyroid hormone (PTH) receptors [1].'

Viral 2C protein inhibitor 1 (compound 6aw) is a potent, broad-spectrum antiviral agent targeting the viral 2C protein, demonstrating relatively low cytotoxicity and a high selectivity index. It effectively inhibits multiple strains of EV-D68, EV-A71, and CVB3 with EC50 values ranging from 0.1 to 3.6 μM [1].

(Met(O)35)-Amyloid β-Protein (1-42) is the oxidized form of Methionine 35 in Aβ42, capable of producing an oligomer size distribution similar to Aβ40. This compound is utilized in Alzheimer’s disease (AD) research [1].

Biotinyl-Ahx-Amyloid β-Protein (1-42) ammonium is an N-terminally biotin-tagged form of Amyloid β-Protein (1-42), the primary component of vascular and parenchymal amyloid deposits associated with Alzheimer's disease [1].

(Gln22)-Amyloid β-Protein (1-42), a Dutch mutation (E22Q) variant of β-Amyloid (1-42), exhibits enhanced fibrillogenic and pathogenic properties [1].

Human beta-amyloid protein 42 (1-7) is a bioactive chemical.

SHP2 protein degrader-1 is a highly efficient allosteric inhibitor targeting SHP2, inducing its degradation and resulting in cell apoptosis; it shows promising potential for studying diseases associated with SHP2.

(Cys47)-HIV-1 tat Protein (47-57) possesses membrane translocation functionality and can serve as a surface derivatization agent for magnetic pharmaceuticals, enhancing their uptake into specific target cells.

FITC-β-Ala-Amyloid β-Protein (1-42) ammonium, a fluorescein isothiocyanate (FITC)-tagged monomer peptide of Aβ1-42, is instrumental in Alzheimer’s disease pathogenesis [1].

Amyloid beta-protein(1-40) Arctic variant (Ab40ARC (E22G)), featuring a glycine at position 22 (Gly22), is a peptide utilized in Alzheimer's disease research [1].

pTH-Related Protein (1-40) (human, mouse, rat) enhances calcium absorption in rat intestinal cells by activating the PTHR1 receptor and the PKCα β signaling pathways. This compound also increases the expression of the parathyroid hormone 1 receptor (PTHR1) and four key proteins involved in transcellular calcium transport: potential vanillin member 6 (TRPV6), calcium-binding protein-D9K (CaBP-D9k), sodium-calcium exchanger 1 (NCX1), and plasma membrane calcium ATPase 1 (PMCA1) [1].

(Glu20)-Amyloid β-Protein (1-42) represents a variant of amyloid β-protein (Aβ) that fibrillizes more slowly due to the Glu20 mutation, which diminishes Aβ42's tendency to aggregate and inhibits the accumulation of this slowly fibrillizing peptide. Amyloid β-protein is the principal constituent of amyloid deposits in the vascular system and brain parenchyma in Alzheimer's disease [1] [2].

(D-Asp1)-Amyloid β-Protein (1-42), a peptide fragment of amyloid β-protein (Aβ), serves as the primary constituent of vascular and parenchymal amyloid deposits associated with Alzheimer's disease [1].

KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor [for potential treatment in cancer].

Protein Kinase Inhibitors 1 Hydrochloride effectively inhibits HIPK2, demonstrating high potency with IC50 values of 136 nM for HIPK1 and 74 nM for HIPK2, alongside a dissociation constant (Kd) of 9.5 nM for HIPK2.

Mitogen-activated protein kinase 1 (MAPK1) activates the p38 NF-κB pathway and regulates cellular processes in sepsis-associated diseases. Its catalytic action phosphorylates substrate proteins, serving as a regulatory switch for their activity [1].

Tau Protein Aggregation-IN-1 (Compound 0c) serves as an inhibitor of Tau protein aggregation, applicable in research related to protein folding disorders including Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease, and prion-based spongiform encephalopathies [1].

Eleven-Nineteen-Leukemia Protein IN-1 is a potent inhibitor of the ENL YEATS domain with an IC50 of 14.5 nM, binding to the ENL protein and increasing its thermal stability in vitro [1].

(Gly22)-Amyloid β-Protein (1-42), a peptide fragment of Amyloid β-Protein (Aβ), plays a crucial role in Alzheimer's disease by forming the main component of vascular and parenchymal amyloid deposits. The Glu22 to Gly22 mutation in Aβ is known to enhance aggregation [1] [2].

'(Lys22)-Amyloid β-Protein (1-42) represents a mutation of the wild-type (WT) Amyloid β-Protein (1-42) peptide [1].'

PTH-Related Protein (1-37) (human, mouse, rat) is a peptide analog of parathyroid-hormone-related protein (pTHrP), which plays a role in the physiological regulation of bone formation [1].

Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.

Acetyl-Heme-Binding Protein 1 (1-21) (human) is a peptide containing the first 21 amino acids of hemopexin Acetyl-Heme-Binding Protein 1, playing a role in heme binding, heme metabolism, and hemoglobin release [1].

Protein kinase D inhibitor 1 (compound 17m) is a potent pan-PKD inhibitor with IC50 values between 17 and 35 nM, demonstrating inhibitory activity in the low nanomolar range. By inhibiting protein kinase D, it effectively suppresses PKD-dependent cortactin phosphorylation [1].

Protein kinase G inhibitor-1 is a potent Protein kinase G inhibitor, IC50= 0.9 uM.

Acetyl-Amyloid β-Protein (1-6) amide, a hexapeptide potentially binding copper(II), is used in Alzheimer's disease research and related disorders [1].

HCV-1 e2 Protein (554-569), a primary antigenic region within the Hepatitis C Virus envelope 2 (e2) protein, contains a putative N-glycosylation site believed to affect immune recognition of e2 [1].

Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate p

Biotinyl-Amyloid β-Protein (1-42) ammonium, a biotinylated form of Amyloid β-Protein (1-42), is used in research on the conversion of Aβ1-42 to Aβ1-40 in the brain [1].

'(Asp37)-Amyloid β-Protein (1-42) [1]' refers to the G37D mutant variant of the wild-type Amyloid-beta (1-42) peptide.

Protein deglycase DJ-1 against-1 is a DJ-1-binding compound that crosses the blood-brain barrier and targets DJ-1 in a dependent manner. This neuroprotective agent holds potential for Parkinson's disease studies.

KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.

Tau protein/α-synuclein-IN-1 is a dual inhibitor that not only impedes tau protein and α-synuclein but also reduces the development of α-syn inclusions in M17D neuroblastoma cells, making it a useful agent in the study of Alzheimer's disease [1].

Myelin Basic Protein (1-11), an encephalitogenic epitope of MBP, facilitates the induction of experimental autoimmune encephalomyelitis (EAE) [1] [2].

HCV-1 e2 Protein (484-499) is a 16-amino acid peptide derived from the envelope 2 protein of the hepatitis C virus, identified in the sera of individuals possessing antibodies to HCV [1].

(Nle35)-Amyloid β-Protein (1-42) ammonium is a peptide.

HCV-1 e2 Protein (554-569) TFA, an antigenic segment of the hepatitis C virus envelope 2 (e2) protein, contains a potential N-glycosylation site that may influence immune recognition of e2 [1].

(Gln22,Asn23)-Amyloid β-Protein (1-40) is a peptide used to study Cerebral Amyloid Angiopathy Mutations [1].

Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42), a peptide fragment derived from amyloid β-protein (Aβ), is crucial in Alzheimer's disease research [1].